MedTrace Logo

Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine

NCT04769778 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-05-19

No results posted yet for this study

Summary

By means of a personalized medicine strategy, investigators are going to evaluate if the treatment with an angiotensin II receptor antagonist (ARAII) in renal transplant patients with the presence of renal progenitor cells (PECs) in the urine is able to prevent the expected loss of glomerular filtration (GFR) observed in this subgroup of patients. In addition, investigators intend to deepen the mechanisms of glomerular damage and glomerular repair involved in the process of chronic allograft damage.

Conditions

  • Chronic Kidney Allograft Nephropathy

Interventions

DRUG

Valsartan 80Mg Oral Tablet

treatment with 80mg /day of valsartan

Sponsors & Collaborators

  • Josep M Cruzado

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769778 on ClinicalTrials.gov